Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

g products in any market, or at any particular time, or that such products will achieve any particular revenue levels. In particular, management's expectations could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), a global company engaged in the ... for the minimally invasive treatment of vascular disease, ... ("BTK") cohort of patients in the Chocolate® Balloon ... 15, 2015 at the 5th Annual Amputation Prevention ...
(Date:8/31/2015)... Aug. 31, 2015   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell ... cryopreservation freeze media and a related ... for smart shippers ("BioLife" or the ... an advanced biopharmaceutical company focused on developing and ...
(Date:8/30/2015)... GENEVA, Switzerland , August 31, 2015 ... join healthbank to ... healthbank , the world,s first citizen-owned health data transaction ... and Netcetera to engineer and bring ...      (Logo: http://photos.prnewswire.com/prnh/20150828/261966) , "Our business ...
Breaking Medicine Technology:Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4
... IRVINE, Calif., Dec. 13, 2010 Masimo ... that a new clinical study demonstrating the accuracy of ... presented last week at the American Association of ... in Las Vegas. The largest gathering of respiratory care ...
... Texas, Dec. 13, 2010 Ascension Orthopedics, Inc., a ... implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. ... from painful primary arthritis with synovial osteochondromotosis at Imperial ... first in continental Europe. The patient was discharged from ...
Cached Medicine Technology:New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 2New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 3New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 4New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 5New Clinical Study Presented at the American Association of Respiratory Care Finds Masimo Rainbow Acoustic Monitoring Accurate for Respiration Rate Assessment 6Ascension Orthopedics Implants PyroTITAN™ in France 2
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo is pleased to ... Outdoor Sauna. After months of extensive engineering and design of our newest sauna model, ... the elements and is offered at a very attractive price-point. , Before outdoor ...
(Date:8/31/2015)... ... 31, 2015 , ... Wyoming Medical Center, an acute care ... Clinical Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural ... is an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing ...
(Date:8/31/2015)... ... , ... Castle Dermatology Institute now welcomes San Fernando Valley skin doctor ... the University of California, Los Angeles. He graduated summa cum laude with a Bachelor ... Medical School. As a nationally recognized Regents Scholar, Dr. Ghasri was given numerous honors ...
(Date:8/31/2015)... ... 2015 , ... “My mother and husband use oxygen therapy and the tubing ... there could be a comfortable way to prevent the irritation, so I invented this.” ... a more secure way to anchor the cannula tubing used in oxygen therapy and ...
Breaking Medicine News(10 mins):Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2
... 2008 South African scientists will gain access ... through an agreement announced today by the European ... Republic of South Africa signed a cooperation agreement ... intergovernmental funding body for EMBO, allowing scientists from ...
... to Rally Residents to Eat Right, Move More and ... Milk Their Diets, ... and downs of different fad diets -- which seem to go in and ... out of three Americans remain overweight or obese., A new campaign crossing ...
... System adds a smile to children, families traveling to and from ... ... Tenn., June 5 3-1-1 Travel,Bag, Inc., a developer of practical carry-on ... Bag,System toiletry cases for families traveling to and from St. Jude,Children,s Research ...
... Tufts University researcher Bess Dawson-Hughes, M.D., chaired ... Osteoporosis Foundation (NOF) Clinician,s Guide to Prevention ... Clinician,s Guide incorporates the World Health Organization ... computer-based tool expected to increase the identification ...
... Inc.,(Nasdaq: NUVO ) today announced the publication ... showing that the R-spondin family of,proteins activate the ... for,cell growth and differentiation during homeostasis and pathogenesis. ... proteins, and,modulated the Wnt pathway by a common ...
... N.J., June 5 Senesco,Technologies, Inc. ("Senesco" or ... details of its continuing preclinical multiple myeloma research. ... animal studies,in which Senesco,s Factor 5A technology, encapsulated ... myeloma tumors when injected,intratumorally., Senesco has continued ...
Cached Medicine News:Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:3-1-1 Travel Bag Donates to St. Jude Children's Research Hospital 2Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 2Health News:Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program 3Health News:Senesco Expands on Preclinical Multiple Myeloma Findings 2Health News:Senesco Expands on Preclinical Multiple Myeloma Findings 3
... It is powerful, lightweight, ... comfortable, soft, durable foam ... pad, covered by machine ... Flexible headband easily adjusts ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: